focus -WSS

focus

author：hotspot 2025-10-01 17:19:32 - browse：4

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Diagnostic tests are hitting their mathematical limits

WSS

With clinical trial data readouts, here's how to spot spin

Takeda, Janssen join wearable maker to measure scratching

Flu vaccine offering decent levels of protection this winter, new data show

FDA investigates CAR

UnitedHealth’s Optum accused of antitrust violations in California

FDA does about

focus

focus

focus

Medical records are filled with copy

ReNAgade cuts staff seven months after raising $300 million

Hepatitis C has a cure — but many Americans still lack access to it

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

At least 13 dead in Texas as scorching temps continue

RSV vaccines may be linked to small increased risk of developing GBS

Alkermes shareholders re

Organ aging and disease risk measured by new blood test

Medicare proposal to cover medical devices draws a mixed reaction

What to do when lifesaving products contribute to climate change

leisure time

Flagship Pioneering launches a new biotech in two countries

RSV vaccines may be linked to small increased risk of developing GBS

Clinical trials giant ICON acquires HumanFirst

Despite FDA concern, risk that CAR

Disappointing trial forces Pfizer to pivot on obesity medicine plans

FDA investigates CAR

explore

focus

focus

explore